Last updated on July 2018

Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics


Brief description of study

The primary objective is to characterize the pharmacokinetics of single doses of ceftobiprole in neonates and infants aged 3 months. The secondary objective is to evaluate safety and tolerability of ceftobiprole in neonates and infants aged 3 months.

Clinical Study Identifier: NCT02527681

Contact Investigators or Research Sites near you

Start Over

Kamal Hamed, MD, MPH

University Children's Hospital of Krak w
Kraków, Poland
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.